sodium injection brand name macugen antiangiogenic medicine treatment neovascular wet agerelated macular degeneration discovered nexstar pharmaceuticals merged gilead sciences licensed eyetech pharmaceuticals osi pharmaceuticals late stage development marketing united states gilead sciences continues receive royalties drugs licensing outside us pegaptanib marketed pfizer approval granted us food drug administration fda december pegaptanib pegylated antivascular endothelial growth factor vegf aptamer single strand nucleic acid binds specificity particular target pegaptanib specifically binds isoform vegf protein plays critical role angiogenesis formation new blood vessels increased permeability leakage blood vessels two primary pathological processes responsible vision loss associated neovascular amd pegaptanib works antagonist vegf injected eye blocks actions vegf reduces growth blood vessels located within eye works control leakage pegaptanib administered mg dose every six weeks intravitreal injection intravitreal injection one administered directly eye specifically vitreous humour jellylike fluid within eye pegaptanib administered designated patient ophthalmologist sterile environment pegaptanib marketed prefilled syringe however syringe contains recommended dose therefore eye care professionals must adjust dose recommended amount pegaptanib underwent several preclinical studies order determine safety efficacy moving clinical trials toxicology studies conducted rhesus monkeys guinea pigs rats mice administration aptamer rhesus monkeys toxic effects exhibited also noted change intraocular pressure immune response taken apiclarification needed aside intravitreal administration pegaptanib also found subcutaneous intravenous routes administration also effective maintaining desired blood plasma rats pegaptanib successful blocking vegfmediated vascular leakage almost entirely sustained release drug tested rabbits found using polylacticcoglycolic acid plga microspheres encapsulated drug minimum dosing frequency weeks maintain desired pharmacological dosing interval carried clinical trials still maintained today phase studies began eyetech pharmaceuticals study conducted patients wet amd doses ranging mg per eye injected eye patients monitored period three months results showed patients stabilization improvement showing improvement signs success phase study eyetech completed phase ii study focusing multiple injections study patients subfoveal choroidal neovascularization cnv secondary amd given multiple intravitreal injections due presence subfoveal cnv patients given secondary treatment photodynamic therapy pdt condition results showed patients received pegaptanib vision stabilized improved patients received pdt alone saw slight improvement however two therapies administered together level improvement reached success phase phase ii trials fda granted fast track designation phase iii clinical trials pegaptanib studied two identical controlled doubleblind randomized clinical studies lasted approximately two years study approximately patients neovascular wet agerelated macular degeneration randomly put groups receive either placebo treatment designated mg mg mg pegaptanib administered intravitreal injections every weeks patients enrolled study approximately received varying doses pegaptanib approximately received placebo injection end first year patients continuing study rerandomized second primary efficacy endpoint study denoted proportion patients lost less letters visual acuity assessed baseline results first year showcased promising results pegaptanib groups treated mg dose primary efficacy endpoint experienced statistically significant result also average pegaptanib mg treated patients well placebo patients continued experience vision loss however rate vision decline significantly lower patients placebo moreover also determined second year treatment less effective first year results primary efficacy endpoint pegaptanib pegaptanib sodium injection approved united states europe brazil canada pending australia filed common side effects pegaptanib average cost pegaptanib approximately per syringes us pegaptanib approved novel drug target treatment treatment amd however last large market sales occurred shortly sales began decline due development effective treatment ranibizumab monoclonal antibody novartis developed offlabel use cheaper httpsenwikipediaorgwikipegaptanib